Compound A723U, a 2-acetylpyridine thiosemicarbazone, was found to inactivate herpes simplex virus (HSV) rLbonucleotide reductase. Inactivation occurred only while the enzyme was catalyzing the reduction of substrate and at a maximum rate of 17 per hr. A723U inhibited virus replication at concentrations that were not toxic to the confluent host cells. It also exhibited mutually potentiated anti-HSV activity with acyclovir (ACV). Sub-inhibitory concentrations of either compound significantly decreased the ED50 of the other compound. As expected, A723U caused the dCTP pool to decrease. However, it also caused the level of ACV-triphosphate to markedly increase. The consequence is a facilitation of the binding of ACV-triphosphate to its target enzyme, HSV DNA polymerase.
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URATE OXIDASE ENCAPS-
IN E R -206 U. Sprandel, Medical Polyclinic, University of Mimich, FRG Erythrccytes have been proposed as cellular carriers for enzyme replacement therapy. Urate oxidase was encapsulated in erythrocytes using different methcds. Average encapsulation was found to be 7 % of the added enzyme activity using a dialysis techique and 1.75 % using a direct henolysis procedure. Binding of enzyme to the membrane could be excluded. Optimum enzyme activity of urate oxidase encapsulated in erythrocytes was found to be at pl 9.5 and 42O C. Suspension of urate oxidase loaded eqthrccytes in uric acid containing n&im was f o l l~ by an initial decrease of uric acid which could be related to the available space inside the cells. After 40 minutes steady-state levels were reached and the further decrease of uric acid showed a direct relation to the added m u n t of entrapped enzyme. Within 24 hours there was a loss of 8 %, within 7 days of 15 % of the enzyme activity, which could be related to h l y s i s . This system was not studied in vivo, since it was not possible to elevate uric acid in a laboratory animal. Haever, these experhats denonstrate, that it would be possible to decrease elevated uric acid levels by urate oxidase loaded erythrocytes in human.
MURINE LYMPHOCYTES AND LYMPHOCYTE LINES SECRETE
207 ADENOSINE DEAMINASE(ADA). Phyllis R. Strauss ,Biology Department, Northeastern University, Boston MA USA ADA is found in the sera of all mammals except the horse and the concentration of serum adenosine (Ado)is correspondingly low (<1 uM).
In this study we examine the possible origin of extracellular ADA. Cells from freshly isolated mouse spleen were incu bated in phosphate buffered saline containing 5 mM glucose and 0.1% bovine serum albumin(BSA) for up to 2 hrs; S49 thymoma cells were incubated in serum-free Dulbecco's modified Eagle's medium containing 0.1% BSA for up to 24 hrs. Cells were rapidly separated from incubation medium by centrifugation through a layer of silicone oil. Intracellular and extracellular ADA was measured by determining the rate of conversion of 3~ Ado(l uM,6 uCi/ml) to inosine+hypoxanthine. To account for extracellular ADA due to cell lysis, intracellular and extracellular lactate dehydrogenase was also measured. On several occasions S49 cells which had been incubated for 20-23 hrs were washed, resuspended and incubated for further time intervals. The appearance of ADA activity in the extracellular medium was time and cell concentration dependent and could not be accounted for by dead or leaky cells. Between 7-10% of the initial intracellular activity was secreted during an 8 hr period. We conclude that lymphocytes secrete -ADA. Supported by NSF PCM 77-25434 and ONR 14-82-K0283.
AN EXPLANATION FOR THE HETEROGENEITY IN B LYMPHOCYTE
208 Ecto-5'-NT activity was measured in human B cells at different stages of development and compared with the B cells' capacity to synthesis Ig in vitro. Ecto-5'-NT activity was higher in adult B cells from peripheral blood, spleen, or lymph node than in B cells from fetal spleen or cord blood (27.9+12, 29.2 and 33.8 vs 5.02 and 5.59t2.8 nmol/hr/l06 cells, respectively). B cell ecto-5'-NT activity increases shortly after birth and is reflected by gradual increases in total lymphocyte ecto-5'-NT activity from 7.0t2.1 in cord blood, to 14.0t4.2 nmol/hr/lo6 cells in normal infants at 6 mo. B cells from cord blood or 6 mo. old infants could synthesize IgM, but not IgG, in response to Epstein Barr virus (EBV). Adult peripheral B cells separated into mature pokeweed mitogen (PWM)-responsive and less mature PWM-nonresponsive fractions by mouse RBC rosetting had equivalent total ecto-5'-NT activity. Thus, in normal human B. cell development, the ability to synthesize IgG in vitro in response to EBV or PWM is acquired subsequent to the acquisition of ecto-5'-NT activity. Therefore, patients with hypogammaglobulinemia might have either normal or low B cell ecto-5'-NT activity depending upon the location of their block in B cell differentiation. Of 11 patients studied, 4 had normal B cell ecto-5'-NT activity while 7 had reduced activity (15.4-58.2 and 2.8-13.2 nmol/hr/10~ cells, respectively). The ability of mitogen-stimulated human T cells or human B lymphoblasts to derive their total purine requirements from inosine 5'-monophosphate (IMP), inosine (HxR) , or hypoxanthine (Hx) was compared. Con A-stimulated T cells were treated with aminop terin (Ampt) to inhibit purine synthesis de novo; thymidine (TdR) was added as a source of pyrimidines. Under these conditions, 30 UM IMP, HxR, and Hx showed com arable abilities to support 3~-~d~ incorporation into DNA or I;H-leucine incorporation into protein at rates equal to those of untreated control cultures. Similar results were found when azaserine was used to inhibit purine synthesis de novo. In parallel experiments, Ampt inhibited the growth of WI-L2 B lymphoblasts by >95% and this growth inhibition could be overcome by 30 pM IMP, HxR, or Hx (plus TdR). However, with cell line #1254, a derivative of WI-L2 lacking detectable ecto-5'-NT activity, only HxR and Hx (plus TdR), but not IMP (plus TdR), were able to restore the growth inhibition due to Ampt. Thus, the catalytic activity of ecto-5'-NT is sufficient to meet the total purine requirements of mitoaen-stimulated human T cells or ra~idlv-dividine human B -. .
ECTO-5'-NUCLEOTIDASE (ECTO-
lymphoblasts, suggesting that this enzyme could play a role in purine salvage when purine synthesis de novo is limited and/or an extracellular source of purine nucleotides is available. Such conditions might exist in developing thymus, spleen and bone marrow where massive cell death occurs. Allopurinol has been shown to inhibit the in vitro growth of leishmaniasis Donovani (1). Recently allopurinol has also been reported effective in the treatment of visceral leishmaniasis with a response rate of 14 out of 16 treated cases (2). The purpose of the present study is to compare the clinical effect of allopurinol versus pentostam at fixed dosages (30 ml/kg and 10 mg/kg daily for 30 days respectively) in the treatment of visceral leishmaniasis. 16 patients were included. 7 patients received allopurinol and 9 pentostam treatment. The clinical effect was monitored using a scoring system. 5 parameters were included each gave 1 point for improvement and 0 point for no improvement. In an average the patients in the allopurinol group scored 1 1/7 point and the pentostam group 3 7/9 point within the first month of treatment. The difference is significant (p < 0.01 Wilcoxon test).
A COMPARATIVE STUDY OF ALLOPURINOL AND
Conclusion: Although allopurinol improve the clinical condition of the patients to some extent pentostam treatment was superior in that respect. Vol. 77, 204-207, 1983. 
